Ratings Jointown Pharmaceutical Group Co., Ltd

Equities

600998

CNE100000W45

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 2025-06-20			5-day change	1st Jan Change
5.030 ^CNY	-0.40%		-7.54%	-1.76%

Jun. 06	Jointown Pharmaceutical Gets Drug Registration for Betamethasone Sodium Phosphate Injection	MT
May. 19	Jointown to Invest 23 Million Yuan Into Pharma-Focused Investment Fund	MT

Summary: Jointown Pharmaceutical Group Co., Ltd

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.

Highlights: Jointown Pharmaceutical Group Co., Ltd

Its low valuation, with P/E ratio at 9.23 and 8.95 for the ongoing fiscal year and 2026 respectively, makes the stock pretty attractive with regard to earnings multiples.
The stock, which is currently worth 2025 to 0.12 times its sales, is clearly overvalued in comparison with peers.
The company appears to be poorly valued given its net asset value.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Analyst opinion has improved significantly over the past four months.

Weaknesses: Jointown Pharmaceutical Group Co., Ltd

The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Revenue estimates are regularly revised downwards for the current and coming years.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings Chart: Jointown Pharmaceutical Group Co., Ltd

Source: Surperformance

ESG chart: Jointown Pharmaceutical Group Co., Ltd

Source: MSCI

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Fundamentals (Composite)	Global Valuation (Composite)	Financial estimates revisions (Composite)	Capi.($)
	JOINTOWN PHARMACEUTICAL GROUP CO., LTD				3.49B
	SIGMA HEALTHCARE LIMITED				23.42B
	HUADONG MEDICINE CO., LTD				10.11B
	SHANGHAI PHARMACEUTICALS HOLDING CO., LTD				8.13B
	SINOPHARM GROUP CO. LTD.				7.33B
	H. LUNDBECK A/S				5.45B
	GALENICA AG				5.25B
	EBOS GROUP LIMITED				4.51B
	Average				8.46B
	Weighted average by Cap.

See all sector ratings

Investor (Composite)

Trader (Composite)

ESG MSCI

Financials

Revenue growth

EPS growth

Capital Efficiency (Composite)

Net Margin

Financial Health (Composite)

Valuation

P/E

EV/Revenue

EV/EBITDA

PBR

Dividend Yield

Revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

Revenue revisions (1 month)

EPS revisions (1 year)

EPS revisions (4 months)

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (4 months)

Analysts' target price evolution (1 year)

Business Predictability

Surprise rates

Analysts' coverage

Analysts' recommendations divergence

Analysts' Target price divergence

Financial estimates divergence

ESG

Environment

Social

Governance

Controversy

Ethical controversies

Human rights controversies

Tax subsidies controversies

Sharia compliant

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes